Current Cancer Drug Targets
Volume 22, 11 Issues, 2022
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
Contents
Current Cancer Drug Targets , Volume 16 - Number 2
Editorial
Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response
, 16(2): 101 - 109Takayo Fukuda, Tomoko Tsuruga, Takako Kuroda, Hiroyuki Nishikawa and Tomohiko Ohta
DOI: 10.2174/1568009615666151030102427
Regulation of Epithelial-Mesenchymal Transition by E3 Ubiquitin Ligases and Deubiquitinase in Cancer
, 16(2): 110 - 118Yasumichi Inoue, Yuka Itoh, Koichi Sato, Fumihiro Kawasaki, Chihiro Sumita, Takahito Tanaka, Daisuke Morishita and Hidetoshi Hayashi
DOI: 10.2174/1568009616666151112122126
The SCF-type E3 Ubiquitin Ligases as Cancer Targets
, 16(2): 119 - 129Kyoko Kitagawa and Masatoshi Kitagawa
DOI: 10.2174/1568009616666151112122231
E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers
, 16(2): 130 - 135Kazuma Masumoto and Masatoshi Kitagawa
DOI: 10.2174/1568009616666151112122336
Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy
, 16(2): 136 - 146Nobumichi Ohoka, Norihito Shibata, Takayuki Hattori and Mikihiko Naito
DOI: 10.2174/1568009616666151112122502
Tribbles-Related Protein Family Members as Regulators or Substrates of the Ubiquitin-Proteasome System in Cancer Development
, 16(2): 147 - 156Satoshi Sakai, Chiharu Miyajima, Chiharu Uchida, Yuka Itoh, Hidetoshi Hayashi and Yasumichi Inoue
DOI: 10.2174/1568009616666151112122645
RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer
, 16(2): 157 - 174Chiharu Uchida and Masatoshi Kitagawa
DOI: 10.2174/1568009616666151112122801
Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment
, 16(2): 175 - 185Erika Giordani, Federica Zoratto, Martina Strudel, Anselmo Papa, Luigi Rossi, Marina Minozzi, Davide Caruso, Eleonora Zaccarelli, Monica Verrico and Silverio Tomao
DOI: 10.2174/1568009615666150817120712
Editor-in-Chief
Ruiwen Zhang
Center for Drug Discovery
University of Houston
Houston, TX
(USA)
Biography
Center for Drug Discovery
University of Houston
Houston, TX
Biography
Biography of Ruiwen Zhang
Ruiwen Zhang is the Robert L. Boblitt Endowed Professor in Drug Discovery and Director of the Drug Discovery Institute at the University of Houston. With over 30 years of experience in the field of biomedical research, particularly in the area of clinical pharmacology and therapeutics, pharmaceutical and toxicological research, Dr. Zhang’s research has been continuously funded by NIH and DoD, and other agencies. He has published more than 230 papers, 2 books, and more than 50 invited reviews/book chapters as well as more than 180 meeting abstracts. For his outstanding contributions in pharmaceutical sciences, Dr. Zhang was elected as a Fellow of American Association for the Advancement of Science (AAAS) in 2009. Dr. Zhang is recently elected as Fellow of National Academy of Inventors (2018).
COPE Compliant
About the Journal
⇨ Journal Home⇨ Editorial Policies⇨ Fabricating and Stating False Information⇨ Research Misconduct⇨ Post Publication Discussions and Corrections⇨ Allegations from Whistleblowers⇨ Editorial Board⇨ Meet the Executive Guest Editor(s)⇨ Board Recruitment Workflow⇨ Short Guide⇨ Join Editorial Board⇨ Indexing Information⇨ Announcements⇨ Endorsements⇨ Authors' Comments
For Authors
For Librarians & Readers
Quick Links
Advertisement
Webmaster Contact: info@benthamscience.net